What is peptide therapy? A consumer research guide
A careful introduction to the broad marketing term “peptide therapy” and why the exact product and regulatory status matter.
6 sections · 3 FAQs · 3 sources
Read guide →Independent research • Source-backed profiles • No paid rankings
Topic pillar
Peptide therapy
Foundational explanations of the term, care models, and questions to ask before contacting a clinic.
Primary research topic: peptide therapy
Guides in this topic
Use these guides together: begin with the overview, follow the verification steps, and confirm time-sensitive regulatory information through the linked primary sources.
Peptides for recovery: how to evaluate the evidence
Recovery claims may refer to injury healing, soreness, performance, or rehabilitation—different outcomes requiring different evidence. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 3 sources
Read guide →Peptides for muscle growth: claims, evidence, and red flags
Muscle-growth advertising can imply drug-like effects, safety, and performance outcomes. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 3 sources
Read guide →Anti-aging peptides: how to research longevity claims
Anti-aging is an expansive marketing claim that may bundle appearance, biomarkers, function, or disease risk. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptides for hair growth: topical versus systemic claims
Hair-related products can be cosmetic, prescription, compounded, topical, or injectable. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptides for skin: cosmetic claims versus medical treatment
Skin peptides span ordinary cosmetics, cosmeceutical marketing, and products making treatment claims. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptides for sleep: evaluating clinic marketing
Sleep claims can mask different symptoms and conditions and are sometimes attached to substances with limited human evidence. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptides for gut health: evidence and marketing claims
Gut-health marketing often combines vague wellness language with specific healing or disease claims. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 3 sources
Read guide →Peptides for joint pain: a claim-checking guide
Joint-pain searches frequently lead to recovery peptides and direct-to-consumer sellers. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →Peptides for injury healing: what human evidence is needed
Injury-healing claims can be especially persuasive when a consumer wants to return to activity quickly. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 3 sources
Read guide →Oral versus injectable peptides: why route changes the question
The same ingredient name may appear in oral, injectable, topical, or nasal products. This guide separates what is known, what is marketed, and what consumers can verify before choosing a provider.
4 sections · 4 FAQs · 2 sources
Read guide →How to research peptide clinical trials without overreading the results
A clinical-trial listing can show that a study exists, but it does not prove that a peptide works, is approved, or is available from a clinic. This step-by-step guide explains how to connect a trial record, posted results, peer-reviewed papers, and FDA status.
6 sections · 6 FAQs · 5 sources
Read guide →FDA approves Lipfendra (enlicitide): what the oral peptide milestone means
FDA approved Lipfendra (enlicitide) on July 17, 2026 as the first oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. The approval is also a notable peptide-development milestone because enlicitide is a highly engineered oral macrocyclic peptide.
6 sections · 6 FAQs · 4 sources
Read guide →Is elamipretide FDA-approved? What Forzinity approval does—and does not—cover
Forzinity is an FDA-approved elamipretide product for a narrow Barth syndrome indication. That approval does not validate every product sold as elamipretide or SS-31, or broader mitochondrial, longevity, exercise, or wellness claims.
6 sections · 6 FAQs · 6 sources
Read guide →Foundayo (orforglipron) FDA approval: why GLP-1 does not always mean peptide
Foundayo is an FDA-approved oral GLP-1 receptor agonist for a specific adult weight-management indication. Its small-molecule chemistry shows that GLP-1 activity does not automatically make a drug a peptide.
6 sections · 6 FAQs · 4 sources
Read guide →Wegovy HD FDA approval: what the 7.2 mg semaglutide label actually covers
Wegovy HD is an FDA-approved higher-strength semaglutide injection for weight reduction in a defined adult population. Its approval does not validate compounded lookalikes, other concentrations, or a provider’s claim that a higher amount is appropriate for every patient.
6 sections · 6 FAQs · 4 sources
Read guide →Yuviwel (navepegritide) FDA approval: the CNP peptide label and its limits
Yuviwel is an FDA-approved C-type natriuretic peptide analog for children aged two years and older with achondroplasia and open growth plates. Its accelerated approval rests on increased annualized growth velocity and requires a study of final adult height.
6 sections · 6 FAQs · 5 sources
Read guide →Hepcludex (bulevirtide) FDA approval: what the peptide drug’s label actually establishes
Hepcludex is the first FDA-approved treatment for chronic hepatitis delta virus infection, but its accelerated approval is narrow: it applies to a specific finished biologic, population, endpoint, and continuing evidence obligation.
6 sections · 6 FAQs · 5 sources
Read guide →Survodutide phase 3 results: evidence, FDA status, and limits in 2026
Two June 2026 phase 3 publications strengthen the evidence for survodutide in studied populations, but trial success is not FDA approval and important outcome, safety, and generalizability questions remain.
6 sections · 6 FAQs · 5 sources
Read guide →Peptide research: preprint vs. peer-reviewed study vs. press release
Publication labels describe different levels of review and completeness; none should be treated as automatic proof that a peptide is safe, effective, approved, or right for a patient.
6 sections · 6 FAQs · 5 sources
Read guide →Placebo-adjusted weight loss: how to read GLP-1 trial percentages
Total change in the treatment arm and the difference versus placebo answer related but different questions; both require the same trial population, time point, analysis, and product context.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov results posted vs. submitted: how to read a peptide study
A completed peptide trial does not automatically have public results, and a submitted result is not the same as a posted result or an FDA approval decision.
6 sections · 6 FAQs · 5 sources
Read guide →PubMed retractions and expressions of concern: how to check peptide research
A PubMed citation is not frozen at publication; linked corrections, concern notices, retractions, comments, and newer versions can materially change how a peptide study should be used.
6 sections · 6 FAQs · 5 sources
Read guide →FDA Drug Trials Snapshots: how to research an approved peptide drug
Drug Trials Snapshots make original approval evidence easier to scan, but they are time-limited summaries—not current labels, complete reviews, or proof for compounded and investigational products.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov primary vs. study completion date: what each means
Primary completion marks final collection for primary outcomes; study completion extends through primary, secondary, and adverse-event data collection—neither date announces success or publication.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov recruitment status: what every label means
Recruitment status describes whether and how a study is enrolling or continuing; it does not report whether a peptide worked, was safe, or received FDA approval.
6 sections · 6 FAQs · 5 sources
Read guide →Peptide study funding and conflicts of interest: a practical check
Funding and conflict disclosures add context to a peptide study, but they should guide closer methods review rather than act as an automatic verdict on the result.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov Record History: how to compare changes in a peptide study
The Record History tab preserves dated study versions so researchers can see what changed, when it changed, and what still needs context.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov protocols and statistical analysis plans: a peptide research guide
Protocols and statistical analysis plans add design and analysis detail that a registry summary or publication may omit, but availability does not prove the study was well designed or followed.
6 sections · 6 FAQs · 5 sources
Read guide →ClinicalTrials.gov data-sharing plans: what an IPD statement really means
An IPD sharing statement records a plan, not proof that data are already public, complete, unrestricted, or independently validated.
6 sections · 6 FAQs · 5 sources
Read guide →Peptide clinical trial phases explained: Phase 1 through Phase 4
A trial phase describes the development question and setting, not a grade of effectiveness or a promise that a peptide will reach approval.
6 sections · 6 FAQs · 4 sources
Read guide →Randomized, blinded, and placebo-controlled peptide trials: what the terms mean
Randomization, masking, and a comparator solve different design problems; seeing all three labels still does not tell you the outcome, effect size, or study quality.
6 sections · 6 FAQs · 4 sources
Read guide →Confidence intervals and p-values in peptide trial results
A p-value does not tell you how large or important an effect is; pair it with the point estimate, confidence interval, outcome, design, and analysis plan.
6 sections · 6 FAQs · 4 sources
Read guide →Mimrylo (rusfertide) FDA approval: what the hepcidin-mimetic peptide label covers
FDA approved the hepcidin-mimetic peptide rusfertide for a defined group of adults with polycythemia vera; the decision does not validate unrelated peptide products or broader uses.
6 sections · 6 FAQs · 4 sources
Read guide →Absolute vs. relative risk in peptide trial results
A relative percentage needs the underlying event rates and time window; absolute risk shows how many more or fewer events occurred in the studied groups.
6 sections · 6 FAQs · 4 sources
Read guide →Noninferiority trials in peptide-drug research: what the result means
A noninferiority trial asks whether a new treatment is not worse than an active comparator by more than a prespecified margin; it does not automatically prove equivalence or superiority.
6 sections · 6 FAQs · 4 sources
Read guide →Clinical trial eligibility criteria: how to read inclusion and exclusion rules for a peptide study
Eligibility criteria describe who a study is designed to enroll; they are not a do-it-yourself diagnosis, a guarantee of enrollment, or proof that results apply outside that population.
6 sections · 6 FAQs · 4 sources
Read guide →